Medicinova, Inc. (MNOV) — Analysis Summary
Medicinova, Inc. (MNOV) has a market cap of $75.80M with year-over-year revenue growth of -59.0%. Net margin stands at -2928.8%. The stock trades at a P/E ratio of -7.0.
Key Takeaways
- Revenue changed -59.0% year-over-year
- Net margin of -2928.8%
- P/E ratio of -7.0
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, MNOV posted revenue growth of -59.0% and trades at a P/E of -7.0.
Medicinova, Inc. (MNOV)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -1287.4% — severe operating losses
Net margin at -1168.2% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
6
Headquarters
LA JOLLA, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.